The present invention provides systems, methods, and devices for electroporation-based therapies (EBTs). Embodiments provide patient-specific treatment protocols derived by the numerical modeling of 3D reconstructions of target tissue from images taken of the tissue, and optionally accounting for one or more of physical constraints or dynamic tissue properties. The present invention further relates to systems, methods, and devices for delivering bipolar electric pulses for irreversible electroporation exhibiting reduced or no damage to tissue typically associated with an EBT-induced excessive charge delivered to the tissue.

Nanosecond pulsed electric field (nsPEF) treatments of a tumor are adjusted based on a size and type of the tumor to stimulate an immune response against the tumor and other tumors in the subject. Calreticulin expression on tumor cells can be detected to confirm treatment. An immune response biomarker can be measured, and further nsPEF treatments can be performed if needed to stimulate or further stimulate the immune response. Cancers that have metastasized may be treated by directly treating a tumor that is most accessible. The treatment can be combined with CD47-blocking antibodies, doxorubicin, CTLA-4-blocking antibodies, and/or PD-1-blocking antibodies. Electrical characteristics of nsPEF treatments can be based on the size, type, and/or strength of tumors and/or a quantity of tumors in the subject.

Presented herein are techniques that enable electroporation of the cells of a recipient of a tissue-stimulating prostheses while the tissue-stimulating prosthesis is implanted in the recipient. Tissue-stimulating prostheses in accordance with embodiments presented herein are configured such that the stimulation electronics (e.g., current sources and integrated circuit) of the prosthesis are not exposed to the high voltages used in electroporation.

A topical composition and method comprising administering physiological effective amounts of at least two active components forskolin combined with one or more lubricating base components. Active components may include one or more of L-arginme free base, hydrochloride salt, ethyl ester or combinations thereof.

Provided herein are systems, methods, and apparatus for electroporation, which may include an applicator; an endoscope, trocar or the like; a generator; and a drug delivery device. The applicator may include a control portion, an insertion tube connected to the control portion, an actuator engaged with the control portion, and a plurality of electrodes comprising a first electrode having a first tip and a second electrode having a second tip. The plurality electrodes may be configured to move between a retracted position and a deployed position in response to actuation by the actuator. A distance between the first tip of the first electrode and the second tip of the second electrode may be greater in the deployed position than in the retracted position. Various treatment methods are also provided.

Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for percutaneous intravascular delivery of pulsed electric fields to achieve such neuromodulation.

The present invention provides systems, methods, and devices for electroporation-based therapies (EBTs). Embodiments provide patient-specific treatment protocols derived by the numerical modeling of 3D reconstructions of target tissue from images taken of the tissue, and optionally accounting for one or more of physical constraints or dynamic tissue properties. The present invention further relates to systems, methods, and devices for delivering bipolar electric pulses for irreversible electroporation exhibiting reduced or no damage to tissue typically associated with an EBT-induced excessive charge delivered to the tissue.

Provided herein are methods of generating a biologically effective unipolar nanosecond electric pulse by superposing two biologically ineffective bipolar nanosecond electric pulses and related aspects, such as electroporation and/or therapeutic applications of these methods to non-invasively target electrostimulation (ES) selectively to deep tissues and organs.

The present invention provides an electroporation device and a method for controlling an electroporation device for facilitating delivering active substances into skin such as stratum corneum while minimizing discomfort of a user by modulating applied voltage pulses. The electroporation device according to the present invention comprises: a measurement unit being configured to provide multiple outputs of one or more resistance measurement voltage pulses for measuring a resistance of skin of a user at a predetermined interval; and an output unit being configured to provide an output of one or more electroporation voltage pulses to the skin of the user based on the resistance of the skin of the user per each output of the one or more resistance measurement voltage pulses.

A dermal device for skincare therapy is provided including: a fluid circuit including a fluid pump and a reservoir; and a dermal interface configured to contact a user's skin, the dermal interface including at least one electrode and part of the fluid circuit having at least one perforation, wherein the at least one electrode is configured to deliver an energy pulse to the contacted skin, wherein the reservoir is configured to hold at least one topical, wherein the fluid pump is configured to pump the at least one topical through the fluid circuit and extrude the at least one topical through the dermal interface.